Navigation Links
Groupe Athena, Inc. Reports Record First Quarter Revenues
Date:10/10/2011

MUMBAI, India, Oct. 10, 2011 /PRNewswire/ -- Groupe Athena, Inc. (Pink sheets GATA.PK) announced today record revenues of $12,211,400 for the first quarter ending September 30, 2011 which generated pretax earnings of $1,566,906, or $.033 per share which is also a record for the same period. With the most recent strong quarter, trailing twelve month (ttm) earnings jumped to nearly $.10 per share. The record quarterly revenue was significant in that it equaled nearly 50% of total revenue for all of the previous fiscal year.

The Company's Chairman, D. Purohit stated, "As our markets continue to expand within India and the region, we expect to see continued strong revenue and earnings growth, and with the recently reported asset additions which allow us to perform more services in-house, our margins are also increasing significantly. We are also very pleased to have a healthy backlog to build on which currently insures our growth well into fiscal 2013."

To review the complete quarterly report please go to www.otcmarkets.com/stock/GATA/quote and click on "Financials."

The company reports it is still committed to funding all capital expenditures entirely from internal cash accruals without any shareholder dilution or debt increases.

As was previously stated, the Indian pharmaceutical industry is increasingly focusing on exports to the United States and GATA is well positioned to help them get their products approved by the FDA for sales in the US. All of these are potential clients and the Company believes it has an advantage over competitors due to the facilities based in India, and their ability to deliver quick feedback to clients that could result in expedited order generation. With recent additions to equipment, the company will continue to take on additional contracts and continue to anticipate further growth.

About Groupe Athena, Inc.

Groupe Athena, Inc. wa
'/>"/>

SOURCE Groupe Athena, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Groupe Athena, Inc. Profits Soar on Record Revenues
2. Groupe Athena, Inc. Provides Guidance on Current Orders
3. Groupe Athena, Inc. Clarifies Previous Guidance
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Spherix Reports Second Quarter Earnings
6. Tapestry Reports Second Quarter 2007 Results
7. Callisto Reports on Second-Quarter 2007 Milestones
8. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
9. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
10. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
11. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Sept. 18, 2014   Regulus Therapeutics Inc ... company leading the discovery and development of innovative ... its ATHENA natural history of disease study in ... disease with no approved therapy. The ATHENA study ... renal function markers such as Glomerular Filtration Rate ...
(Date:9/18/2014)... and ROCKVILLE, Md. , ... SPPI ), a biotechnology company with fully integrated ... in hematology and oncology, and CASI Pharmaceuticals, Inc. (Nasdaq: ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a primary focus on China ...
(Date:9/18/2014)... Sept. 18, 2014  RXi Pharmaceuticals Corporation ... company focused on discovering, developing and commercializing ... using RNA-targeted technologies, today announced that the Company,s ... Geert Cauwenbergh , will present at the ... on Wednesday, September 24, 2014 at 11:20 ...
Breaking Medicine Technology:Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 4Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 5Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 6Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 2Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 3Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 4Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 5Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 6Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 7Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 8Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 9Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 10RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 2RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 3
... 2011 On Sunday, August 21, veterinary cardiologists are ... the Mobile Dog Heart Health Tour will stop with ... examinations at Peters Park Dog Run. (Photo: ... free heart health screenings, veterinarians will be available to ...
... Unilife Corporation ("Unilife" or the "Company") (NASDAQ: ... it has finalized a previously disclosed Equipment Financing ... $10 million in available funding. This agreement will ... finance the automated assembly line now manufacturing the ...
Cached Medicine Technology:Free Dog Heart Health Screenings Available August 21 in Boston 2Unilife Signs $10 Million Equipment Financing Agreement 2Unilife Signs $10 Million Equipment Financing Agreement 3Unilife Signs $10 Million Equipment Financing Agreement 4
(Date:9/18/2014)... Qualis Health, one of the nation’s leading population ... “Advancing Primary Care through the Patient-Centered Medical Home Model ... Jeff Hummel, MD, MPH and Peggy C. Evans, PhD, ... the work of becoming a Patient-Centered Medical Home (PCMH) ... such as generating and providing useful data that can ...
(Date:9/18/2014)... developed a new method to study Ebola virus in ... Conservation Society (WCS)-led research, published today in the journal ... of fecal samples from wild great apes to identify ... This represents a new tool for performing large, population-scale ... virus is studied and improve our understanding of the ...
(Date:9/18/2014)... recommending that elderly men should not be routinely screened ... to a new study led by researchers at Henry ... online in JAMA Internal Medicine , focused on ... test for prostate cancer., "We found that the effect ... elderly men in particular has been minimal at best," ...
(Date:9/18/2014)... 2014 With the swift industrial development ... such as smart phones, tablets and PDAs, a complete ... mobile devices are viewed these days. From only being ... becoming a mode for creating and delivering content while ... way. , The complete makeover of this ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 A sold-out ... community advocates, and volunteers supported United Way of ... Chefs and Fine Wines” event Monday, Sept. 15. Proceeds ... health initiatives in Westchester and Putnam, such as providing ... steering teens away from risky behaviors like drug and ...
Breaking Medicine News(10 mins):Health News:Advancing Primary Care Through PCMH and HIT: New White Paper Connects the Dots 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3Health News:Professional recommendations against routine prostate cancer screening have little effect 2Health News:Transparency Market Research: M-health Market Study 2018 2Health News:Transparency Market Research: M-health Market Study 2018 3Health News:Transparency Market Research: M-health Market Study 2018 4Health News:United Way Celebrates “Best Chefs and Fine Wines” at Sold-Out Culinary Event 2Health News:United Way Celebrates “Best Chefs and Fine Wines” at Sold-Out Culinary Event 3
... people who have optic nerve damage might be at ... the study researchers involved 25 people with visual impairment. ... days, and their results were compared with those of ... that those with optic nerve disease were 20-times more ...
... inflammation of the liver and can cause complications such ... the hepatitis B vaccine is recommended for infants. Previous ... against infection for up to 10 years. However, a ... 10 years. ,Researchers followed eight-hundred-and-forty-one Alaska natives vaccinated ...
... of the expectant mother. Now a new study suggests ... of preeclampsia in the pregnant women. ,The ... with periodontitis with atherosclerosis to preeclampsia. Such an oral ... abuse like smoking, etc. The basic reason for setting ...
... and vitamin B12 are safe and effective in reducing the ... a stroke . According to researchers stroke patients have a ... healthy peers due to higher levels of plasma homocysteine in ... of hip fracture. ,The study was initiated to ...
... in Japan, even after the country has banned the shots of ... of the must-have vaccines to be given to children before they ... journal Lancet in 1998 had published a paper relating the MMR ... there had been considerable fall in vaccinating children with MMR (Measles, ...
... benefits of alcohol consumption and cardiovascular disease researchers studied ... // moderate levels of alcohol (one to seven drinks ... eight drinks per week), and did not consume any ... first to focus on the association between alcohol intake ...
Cached Medicine News:
Caspar Curette, 250 mm, 10"....
Bone Curette, 160 mm...
Bone Curette, 145 mm...
Bone Currettes...
Medicine Products: